Closed-loop insulin delivery improves glucose control in type 1 diabetes

  • Tauschmann M & al.
  • Lancet
  • 1 Oct 2018

  • curated by Antara Ghosh
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Use of a day-and-night hybrid closed-loop insulin delivery system in adults, adolescents and children with sub-optimally controlled type 1 diabetes was associated with improved glucose control and reduced hypoglycaemic risk.

Why this matters

  • Findings from this study along with previous evidence support adoption of closed-loop technology in clinical practice across all age groups.

Study design

  • 86 patients (aged, ≥6 years) with type 1 diabetes with suboptimal glycaemic control who were treated with insulin pump for at least 3 months were evaluated.
  • Patients were randomly allocated to either hybrid closed-loop (n=46) or sensor-augmented pump (n=40; control group) therapy over 12 weeks of free living.
  • Funding: Juvenile Diabetes Research Foundation.

Key results

  • Proportion of time  glucose was within the target range (3.9–10.0 mmol/L) was higher in the closed-loop vs control group (mean difference in change [MDc], 10.8 percentage points; P<.0001>
  • The proportion of time when glucose was
  • HbA1c concentrations were significantly lower after closed-loop vs control intervention (MDc, 0.36%; P<.0001>
  • Adverse events included diabetic ketoacidosis because of infusion set failure (n=1; closed-loop group), hyperglycaemia (n=2 in each group), and 13 and 3 other adverse events in the closed-loop and control groups, respectively.

Limitations

  • Open-label trial.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit